APITOPE TECHNOLOGY BRISTOL LTD has a total of 76 patent applications. Its first patent ever was published in 2001. It filed its patents most often in EPO (European Patent Office), China and Mexico. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CHUGH SUMANT S, SURVAC APS and EXOCELL INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | China | 6 | |
#3 | Mexico | 6 | |
#4 | Poland | 6 | |
#5 | Brazil | 5 | |
#6 | United Kingdom | 5 | |
#7 | United States | 5 | |
#8 | WIPO (World Intellectual Property Organization) | 5 | |
#9 | Hong Kong | 4 | |
#10 | New Zealand | 4 | |
#11 | Canada | 3 | |
#12 | Ecuador | 3 | |
#13 | Hungary | 3 | |
#14 | Republic of Korea | 3 | |
#15 | Norway | 3 | |
#16 | Colombia | 2 | |
#17 | EAPO (Eurasian Patent Organization) | 1 | |
#18 | Israel | 1 | |
#19 | Philippines | 1 | |
#20 | Singapore | 1 | |
#21 | Ukraine | 1 | |
#22 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Machines |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Wraith David | 36 |
#2 | Streeter Heather Barbara | 31 |
#3 | Mazza Graziella | 29 |
#4 | Wraith David Cameron | 28 |
#5 | Ponsford Mary | 20 |
#6 | Anderton Stephen Mark | 18 |
#7 | Streeter Heather | 17 |
#8 | Ponsford Frances Mary | 9 |
#9 | Cameron Wraith David | 3 |
#10 | Barbara Streeter Heather | 2 |
Publication | Filing date | Title |
---|---|---|
GB0908515D0 | Peptide | |
EP2211892A2 | Compositions comprising myelin basic protein peptides and medical uses thereof | |
GB0800962D0 | Conposition | |
GB0723712D0 | Peptides | |
GB0721430D0 | Composition | |
GB0707933D0 | Disease markers | |
NZ523841A | Selection of tolerogenic peptides that can bind MHC class I or II molecules without further processing and their uses in pharmaceuticals and in hypersensitivity disorders |